2024-09-20
ENA first public
ERC000050
ENA-CHECKLIST
EMBL Heidelberg
INSDC center name
public
INSDC status
ERS21070956
SRA accession
spire_mag_01636117
Submitter Id
Many fragments with little to no review of assembly other than reporting of standard assembly statistics
assembly quality
megahit 1.2.9
assembly software
default
binning parameters
metabat 2.12.1
binning software
human digestive system
broad-scale environmental context
EBI-EMG
broker name
missing: third party data
collection date
85.85
%
completeness score
checkm2 0.1.3
completeness software
4.0
%
contamination score
This sample represents a Third Party Annotation (TPA) binned metagenome assembled from the metagenomic run ERR2750216 of study ERP110263.
description
stool
environmental medium
not provided
geographic location (country and/or sea)
missing: third party data
DD
geographic location (latitude)
missing: third party data
DD
geographic location (longitude)
metagenome-assembled genome
investigation type
human gut metagenome
isolation_source
human gut
local environmental context
human gut metagenome
metagenomic source
Bacteroides uniformis
organism
Abstract (1):Empiric probiotics are commonly consumed in healthy individuals as means of life quality improvement and disease prevention. However, evidence of probiotic gut mucosal colonization efficacy remains sparse and controversial. We metagenomically characterized the murine and human mucosal-associated gastrointestinal microbiome and found it to only partially correlate with stool microbiome. A sequential invasive multi-omics measurement at baseline and during consumption of an 11-strain probiotic combination or placebo, demonstrated that probiotics remain viable upon gastrointestinal passage. In colonized, but not germ-free mice, probiotics encountered a marked mucosal colonization resistance. In contrast, humans featured a person-, region- and microbial-specific mucosal colonization patterns, hallmarked by differential baseline host and microbiome features, but indistinguishable by probiotics presence in stool. Consequently, probiotics induced a transient, highly-individualized impact on mucosal community structure and gut transcriptome. Collectively, empiric probiotics supplementation may be limited in universally and persistently impacting the gut mucosa, meriting development of new personalized probiotic approaches.Abstract (2):Probiotics are widely prescribed for prevention of antibiotics-associated dysbiosis and related adverse effects. However, probiotic impact on post-antibiotic reconstitution of the gut mucosal host-microbiome niche remains elusive. We invasively examined the effects of multi-strain probiotics or autologous fecal microbiome transplantation (aFMT) on post-antibiotic reconstitution of the murine and human mucosal microbiome niche. Contrary to homeostasis, antibiotic perturbation enhanced probiotics colonization in the human mucosa, but only mildly improved colonization in mice. Compared to spontaneous recovery, probiotics induced a markedly delayed and persistently-incomplete indigenous stool/mucosal microbiome reconstitution and gut transcriptome recovery to steady-state configuration, while aFMT induced a rapid and near-complete recovery within days of administration. In-vitro, Lactobacillus-secreted soluble factors contributed to probiotics-induced microbiome inhibition. Collectively, potential post-antibiotic probiotic benefits may be offset by a compromised microbiome and host recovery, highlighting a need of developing aFMT or personalized probiotic approaches achieving mucosal protection, without compromising microbiome recolonization in the antibiotics-perturbed host.
project name
SAMEA4845498
sample derived from
Bacteroides uniformis
scientific_name
NextSeq 500
sequencing method
multi-marker approach
taxonomic identity marker
binned metagenome: spire_mag_01636117
title